Transplant antibody-mediated rejection: guiding effective treatments
The British Kidney Patient Association, UK Transplantation Clinical Study Group and the James Lind Alliance Transplant Priority Setting Partnership highlighted the need for more research on renal transplant rejection. This idea aligned with a clinical trial proposal to assess the efficacy of available treatments for acute antibody-mediated rejection in renal transplantation. TAR:GET-1 (NCT03994783) is now a UK multi-centre randomised controlled trial funded by Kidney Research UK and NIHR Health Technology Assessment Programme. Dr Michelle Willicombe, Imperial College London, is Chief Investigator; the trial is now closed to recruitment and analysis is underway.